P+P advises the management of PharmaZell on acquisition by Bridgepoint

PharmaZell is a leading independent manufacturer of active pharmaceutical ingredients (API) on the extremely stabile and specialized API market. The company has a diversified portfolio of more than 70 ingredients and has a leading position in the industry with an entire line of products for treating respiratory, inflammatory and liver illnesses that can benefit from lifestyle changes. Many of the company's products require special treatment processes and/or technologies. PharmaZell is headquartered in Raubling (near Munich) operates four state-of-the-art manufacturing and R&D locations in Germany, Italy and India and employs over 900 people worldwide.
Bridgepoint manages assets of over EUR 29 billion from global investors. These include public and private pension funds, asset managers, family offices, independent agencies and insurance companies throughout the entire world.

P+P Pöllath + Partners advised the management group of CEO Oliver Bolzern with the following team:

• Dr. Benedikt Hohaus (partner, lead, MPP, M&A/private equity)
• Dr. Roman Stenzel (counsel, MPP, M&A/private equity)
• Silke Simmer (associate, MPP, M&A/private equity, all Munich)